The 23rd JFCR-ISCC
New Antitumor Agents under Development in the US, Europe and Japan

2018 December 13 (Thu) 13:00 -19:00
December 14 (Fri) 9:00 -18:00

Miraikan
National Museum of Emerging Science and Innovation
2-3-6, Aomi, Koto-ku, Tokyo, Japan

**Session 1**
Immunotherapy resistance: Primary and acquired resistance mechanisms

Hassane M. Zarour  
UPMC Hillman Cancer Center
Therapeutic strategies to reverse tumor-induced T cell dysfunction

Takashi Ishida  
Iwate Medical Univ.
Mogamulizumab sensitivity and resistance; CCR4 mutations

Yoshihiro Ohue  
National Cancer Center
Analysis of immunological resistance to anti-tumor immunity

**Session 2**
Cutting edge of immuno-oncology research

Andrea Schietinger  
MSKCC
Molecular programs defining T cell dysfunction in tumors

Tadashi Yokosuka  
Tokyo Med. Univ.
Molecular imaging unveils a mechanism of T cell activation regulation by immune checkpoint microclusters

**Session 3**
New drugs under clinical or preclinical investigations

Jaap Verweij  
Erasmus Univ.
OMO-1, a novel highly selective MET inhibitor

Janet Franklin  
Amgen Inc.
Blinatumomab, a first-in-class bispecific T engager (BiTE) antibody against CD19/CD3

Daisuke Morishita  
Chordia Therapeutics Inc.
A novel therapeutic agent for relapsed and refractory lymphomas

**Session 4**
Epigenetic and DNA damage response inhibitors

Ross Levine  
MSKCC
Role of mutations in epigenetic regulators in myeloid transformation

Yves Pommier  
NCI, NIH
DNA damage response inhibitors: PARP, ATR, HDAC inhibitors, and SLFN11: Update and perspective

**Special Lecture**
Defining a cancer dependency map

William Hahn  
Dana-Farber Cancer Institute

**Session 5**
CAR-T cell immunotherapy: Current status and future directions

Naoki Hosen  
Osaka Univ.
The activated conformation of integrin β7 is a novel multiple myeloma-specific target for CAR T-cell therapy

Koji Tamada  
Yamaguchi Univ.
Primé CAR-T cell technology for treatment of solid cancers

Contact: Cancer Chemotherapy Center, Japanese Foundation for Cancer Research
jfcr-iscc@ml.jfcr.or.jp